185 related articles for article (PubMed ID: 25428641)
21. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
[TBL] [Abstract][Full Text] [Related]
22. Update on NewLink's HyperAcute cancer immunotherapy products.
Riedmann EM
Hum Vaccin Immunother; 2012 Jul; 8(7):847. PubMed ID: 23213663
[No Abstract] [Full Text] [Related]
23. Immunotherapeutic approaches in pancreatic cancer.
Stieler J
Recent Results Cancer Res; 2008; 177():165-77. PubMed ID: 18084958
[TBL] [Abstract][Full Text] [Related]
24. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.
Zheng R; Liu X; Zhang Y; Liu Y; Wang Y; Guo S; Jin X; Zhang J; Guan Y; Liu Y
Front Immunol; 2024; 15():1383978. PubMed ID: 38756774
[TBL] [Abstract][Full Text] [Related]
25. Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto D; Wallet SM; Hughes SJ
Pharmacol Ther; 2016 Oct; 166():9-29. PubMed ID: 27343757
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
Yee NS
Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.
Keenan B; Jaffee EM
Ann N Y Acad Sci; 2013 May; 1284():12-6. PubMed ID: 23651188
[TBL] [Abstract][Full Text] [Related]
28. Q&A: Evidence presenter. Interview by Marian Turner.
Palucka K
Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364
[No Abstract] [Full Text] [Related]
29. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
30. New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation.
Curran MA; Glisson BS
Annu Rev Med; 2019 Jan; 70():409-424. PubMed ID: 30379596
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
Xuan W; Yan Y; Wan M; Wu X; Ji D; Wang L; Lin C; Chen Y; Yu Y; Zhang X
Int Immunopharmacol; 2015 Jul; 27(1):95-103. PubMed ID: 25907246
[TBL] [Abstract][Full Text] [Related]
32. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials of vaccines for immunotherapy in pancreatic cancer.
Plate J
Expert Rev Vaccines; 2011 Jun; 10(6):825-36. PubMed ID: 21692703
[TBL] [Abstract][Full Text] [Related]
34. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.
Osborne N; Sundseth R; Burks J; Cao H; Liu X; Kroemer AH; Sutton L; Cato A; Smith JP
Cancer Immunol Immunother; 2019 Oct; 68(10):1635-1648. PubMed ID: 31549214
[TBL] [Abstract][Full Text] [Related]
35. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
36. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
[TBL] [Abstract][Full Text] [Related]
37. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.
Ghidini M; Lampis A; Mirchev MB; Okuducu AF; Ratti M; Valeri N; Hahne JC
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33383713
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Chen J; Xiao-Zhong G; Qi XS
J Immunol Res; 2017; 2017():8282391. PubMed ID: 28265583
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
40. Directing dendritic cell immunotherapy towards successful cancer treatment.
Sabado RL; Bhardwaj N
Immunotherapy; 2010 Jan; 2(1):37-56. PubMed ID: 20473346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
